Movement Alert｜Teva Pharmaceutical Rises 6.95% in Regular Trading, Q2 Revenue Beats Expectations and Full-Year Guidance Raised

Market Focus07-29

On July 29, Teva Pharmaceutical rose 6.95% in regular trading, trading at $35.27/share, with turnover of $87.75 million. The rally was driven by the company's Q2 earnings release featuring above-consensus revenue and an upward revision to full-year guidance.

Teva reported Q2 net revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. The company simultaneously raised its full-year revenue guidance to $16.5 billion–$16.85 billion, up from the prior range of $16.4 billion–$16.8 billion, while reaffirming Non-GAAP EPS guidance of $1.91–$2.11. However, Q2 adjusted EPS came in at just $0.02, sharply missing the $0.25 estimate and representing a 97% year-over-year decline. Despite the earnings miss, the market prioritized the revenue beat and guidance upgrade as signals of sustained top-line momentum.

Supporting sentiment, Teva has advanced multiple pipeline and biosimilar initiatives in recent months, including a global licensing deal for an Ocrevus biosimilar, the European launch of Eylea biosimilar Ahzantive, submission of ecopipam NDA for pediatric Tourette syndrome, and a $400 million Blackstone-backed funding deal for duvakitug development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119569537?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 21:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119569537","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Teva Pharmaceutical Rises 6.95% in Regular Trading, Q2 Revenue Beats Expectations and Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On July 29, Teva Pharmaceutical rose 6.95% in regular trading, trading at $35.27/share, with turnover of $87.75 million. The rally was driven by the company's Q2 earnings release featuring above-consensus revenue and an upward revision to full-year guidance.</p><p>Teva reported Q2 net revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. The company simultaneously raised its full-year revenue guidance to $16.5 billion–$16.85 billion, up from the prior range of $16.4 billion–$16.8 billion, while reaffirming Non-GAAP EPS guidance of $1.91–$2.11. However, Q2 adjusted EPS came in at just $0.02, sharply missing the $0.25 estimate and representing a 97% year-over-year decline. Despite the earnings miss, the market prioritized the revenue beat and guidance upgrade as signals of sustained top-line momentum.</p><p>Supporting sentiment, Teva has advanced multiple pipeline and biosimilar initiatives in recent months, including a global licensing deal for an Ocrevus biosimilar, the European launch of Eylea biosimilar Ahzantive, submission of ecopipam NDA for pediatric Tourette syndrome, and a $400 million Blackstone-backed funding deal for duvakitug development.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Teva Pharmaceutical Rises 6.95% in Regular Trading, Q2 Revenue Beats Expectations and Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Teva Pharmaceutical Rises 6.95% in Regular Trading, Q2 Revenue Beats Expectations and Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-29 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 29, Teva Pharmaceutical rose 6.95% in regular trading, trading at $35.27/share, with turnover of $87.75 million. The rally was driven by the company's Q2 earnings release featuring above-consensus revenue and an upward revision to full-year guidance.</p><p>Teva reported Q2 net revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. The company simultaneously raised its full-year revenue guidance to $16.5 billion–$16.85 billion, up from the prior range of $16.4 billion–$16.8 billion, while reaffirming Non-GAAP EPS guidance of $1.91–$2.11. However, Q2 adjusted EPS came in at just $0.02, sharply missing the $0.25 estimate and representing a 97% year-over-year decline. Despite the earnings miss, the market prioritized the revenue beat and guidance upgrade as signals of sustained top-line momentum.</p><p>Supporting sentiment, Teva has advanced multiple pipeline and biosimilar initiatives in recent months, including a global licensing deal for an Ocrevus biosimilar, the European launch of Eylea biosimilar Ahzantive, submission of ecopipam NDA for pediatric Tourette syndrome, and a $400 million Blackstone-backed funding deal for duvakitug development.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"","article_id":"1119569537","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119569537","pubTimestamp":1785332275,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 29, Teva Pharmaceutical rose 6.95% in regular trading, trading at $35.27/share, with turnover of $87.75 million. The rally was driven by the company's Q2 earnings release featuring...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"走势提醒|梯瓦制药常规交易上涨6.95%，第二季度收入超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"On July 29, Teva Pharmaceutical rose 6.95% in regular trading, trading at $35.27/share, with turnover of $87.75 million. The rally was driven by the company's Q2 earnings release featuring above-consensus revenue and an upward revision to full-year guidance.Teva reported Q2 net revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. The company simultaneously raised its full-year revenue guidance to $16.5 billion–$16.85 billion, up from the prior range of $16.4 billion–$16.8 billion, while reaffirming Non-GAAP EPS guidance of $1.91–$2.11. However, Q2 adjusted EPS came in at just $0.02, sharply missing the $0.25 estimate and representing a 97% year-over-year decline. Despite the earnings miss, the market prioritized the revenue beat and guidance upgrade as signals of sustained top-line momentum.Supporting sentiment, Teva has advanced multiple pipeline and biosimilar initiatives in recent months, including a global licensing deal for an Ocrevus biosimilar, the European launch of Eylea biosimilar Ahzantive, submission of ecopipam NDA for pediatric Tourette syndrome, and a $400 million Blackstone-backed funding deal for duvakitug development.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119569537","isCrawlerRequest":true}